These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25531722)

  • 1. Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.
    O'Kane GM; Lyons TG; Colleran GC; Ahmad MW; Alken S; Kavanagh EC; Fitzpatrick D; Murray B; Kelly CM
    Oncol Res Treat; 2014; 37(12):757-60. PubMed ID: 25531722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
    Wachsmann JW; Ganti R; Peng F
    Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipilimumab-induced colitis on FDG PET/CT.
    Lyall A; Vargas HA; Carvajal RD; Ulaner G
    Clin Nucl Med; 2012 Jun; 37(6):629-30. PubMed ID: 22614208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab-induced colitis in patients with metastatic melanoma.
    De Felice KM; Gupta A; Rakshit S; Khanna S; Kottschade LA; Finnes HD; Papadakis KA; Loftus EV; Raffals LE; Markovic SN
    Melanoma Res; 2015 Aug; 25(4):321-7. PubMed ID: 25933207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.
    Lipson EJ; Bodell MA; Kraus ES; Sharfman WH
    J Clin Oncol; 2014 Jul; 32(19):e69-71. PubMed ID: 24493726
    [No Abstract]   [Full Text] [Related]  

  • 6. 18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab.
    Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
    Clin Nucl Med; 2016 Feb; 41(2):156-8. PubMed ID: 26545022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab-induced acute severe colitis treated by infliximab.
    Pagès C; Gornet JM; Monsel G; Allez M; Bertheau P; Bagot M; Lebbé C; Viguier M
    Melanoma Res; 2013 Jun; 23(3):227-30. PubMed ID: 23458760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab-induced hepatitis on 18F-FDG PET/CT in a patient with malignant melanoma.
    Raad RA; Pavlick A; Kannan R; Friedman KP
    Clin Nucl Med; 2015 Mar; 40(3):258-9. PubMed ID: 25290291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab-Induced Adrenalitis: A Possible Pitfall in 18F-FDG-PET/CT.
    Bacanovic S; Burger IA; Stolzmann P; Hafner J; Huellner MW
    Clin Nucl Med; 2015 Nov; 40(11):e518-9. PubMed ID: 26164177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab.
    van der Hiel B; Blank CU; Haanen JB; Stokkel MP
    Clin Nucl Med; 2013 Apr; 38(4):e182-4. PubMed ID: 23455528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
    Tirumani SH; Ramaiya NH; Keraliya A; Bailey ND; Ott PA; Hodi FS; Nishino M
    Cancer Immunol Res; 2015 Oct; 3(10):1185-92. PubMed ID: 26100356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete response of multiple melanoma brain metastases after treatment with temozolomide.
    Dvorak J; Melichar B; Zizka J; Hadzi-Nikolov D; Petera J
    Onkologie; 2004 Apr; 27(2):171-4. PubMed ID: 15138351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital.
    Rastogi P; Sultan M; Charabaty AJ; Atkins MB; Mattar MC
    World J Gastroenterol; 2015 Apr; 21(14):4373-8. PubMed ID: 25892889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis.
    Barina AR; Bashir MR; Howard BA; Hanks BA; Salama AK; Jaffe TA
    Abdom Radiol (NY); 2016 Feb; 41(2):207-14. PubMed ID: 26867901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory Orbitopathy Associated With Ipilimumab.
    Sheldon CA; Kharlip J; Tamhankar MA
    Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S155-S158. PubMed ID: 26068559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary malignant melanoma of the lung: a case report and review of the literature.
    Kundranda MN; Clark CT; Chaudhry AA; Chan V; Daw HA
    Clin Lung Cancer; 2006 Jan; 7(4):279-81. PubMed ID: 16512984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
    Boasberg P; Hamid O; O'Day S
    Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
    Woźniak S; Mackiewicz-Wysocka M; Krokowicz Ł; Kwinta Ł; Mackiewicz J
    Oncol Res Treat; 2015; 38(3):105-8. PubMed ID: 25792081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.
    Barjaktarevic IZ; Qadir N; Suri A; Santamauro JT; Stover D
    Chest; 2013 Mar; 143(3):858-861. PubMed ID: 23460165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?
    Dick J; Enk A; Hassel JC
    Dermatology; 2015; 230(1):8-10. PubMed ID: 25531526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.